Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL2302 vs. Tezspire in Healthy Subjects
NCT07327697Phase 1Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Dec 2025
- Primary completion
- Jul 2026
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, randomised, double-blind trial of tezepelumab in asthma (2 arms), sponsored by Qilu Pharmaceutical. Primary endpoint: Pharmacokinetics. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
03
Conditions
asthma
Beyond the preview
Go deeper on NCT07327697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07327697.